CA3221494A1 - Methode, kit et systeme de detection de cancer - Google Patents

Methode, kit et systeme de detection de cancer Download PDF

Info

Publication number
CA3221494A1
CA3221494A1 CA3221494A CA3221494A CA3221494A1 CA 3221494 A1 CA3221494 A1 CA 3221494A1 CA 3221494 A CA3221494 A CA 3221494A CA 3221494 A CA3221494 A CA 3221494A CA 3221494 A1 CA3221494 A1 CA 3221494A1
Authority
CA
Canada
Prior art keywords
mir
hsa
cancer
mirna
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3221494A
Other languages
English (en)
Inventor
Andrew Zhang
Hai HU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mironcol Inc
Original Assignee
Mironcol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mironcol Inc filed Critical Mironcol Inc
Publication of CA3221494A1 publication Critical patent/CA3221494A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Databases & Information Systems (AREA)
  • Immunology (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Software Systems (AREA)
  • Hospice & Palliative Care (AREA)
  • Evolutionary Computation (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode, un kit et un système permettant de détecter un ou plusieurs cancers humains avec une grande précision. Après détermination d'un profil d'expression d'un ensemble de biomarqueurs de miARN comprenant un ou plusieurs miARN sur la base d'un échantillon de biopsie liquide provenant d'un sujet, un indice de diagnostic est calculé, sur la base duquel le sujet peut être classé comme ayant un cancer ou non. Un modèle de biomarqueur de 4 miARN démontre des sensibilités exceptionnellement élevées de 99,0 à 100 % pour les cancers du poumon et de l'estomac, de 83,0 à 99,0 % pour les cancers du tractus biliaire, de la vessie, colorectal, de l'?sophage, glial, du foie, du pancréas et de la prostate, et de 68,2 à 72,0 % pour le cancer de l'ovaire et le sarcome, tout en maintenant une spécificité de 99,3 %.
CA3221494A 2021-06-09 2022-06-07 Methode, kit et systeme de detection de cancer Pending CA3221494A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208506P 2021-06-09 2021-06-09
US63/208,506 2021-06-09
PCT/US2022/032423 WO2022261039A2 (fr) 2021-06-09 2022-06-07 Méthode, kit et système de détection de cancer

Publications (1)

Publication Number Publication Date
CA3221494A1 true CA3221494A1 (fr) 2022-12-15

Family

ID=84426392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3221494A Pending CA3221494A1 (fr) 2021-06-09 2022-06-07 Methode, kit et systeme de detection de cancer

Country Status (6)

Country Link
EP (1) EP4352266A4 (fr)
JP (1) JP2024523848A (fr)
CN (1) CN117500941A (fr)
AU (1) AU2022289858A1 (fr)
CA (1) CA3221494A1 (fr)
WO (1) WO2022261039A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799648B (zh) * 2017-06-29 2024-03-22 东丽株式会社 用于检测肺癌的试剂盒、装置和方法
CA3098105A1 (fr) * 2018-04-25 2019-10-31 Toray Industries, Inc. Kit, dispositif et procede de detection d'un cancer de la vessie
CN117802235B (zh) * 2022-09-30 2025-08-19 上海思路迪生物医学科技有限公司 血液胞外囊泡miRNA在卵巢癌诊断中的应用
KR20250159710A (ko) * 2023-03-13 2025-11-11 미론콜 다이아그노스틱스 리미티드 암 진단 모델의 개발 방법 및 암 검출 방법 개발에서의 이의 용도
WO2025128926A1 (fr) * 2023-12-13 2025-06-19 Amazon Technologies, Inc. Méthodes d'identification et de traitement d'individus présentant un risque élevé de cancer
WO2026015599A1 (fr) * 2024-07-10 2026-01-15 Mironcol Diagnostics, Ltd. Classificateurs de diagnostic basés sur l'apprentissage automatique pour prédire un tissu cancéreux d'origine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9495515B1 (en) * 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US20120041274A1 (en) * 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20150011414A1 (en) * 2012-01-16 2015-01-08 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US9708667B2 (en) * 2014-05-13 2017-07-18 Rosetta Genomics, Ltd. MiRNA expression signature in the classification of thyroid tumors
EP3191602A1 (fr) * 2014-09-09 2017-07-19 Istituto Europeo di Oncologia S.r.l. Procédés de détection du cancer du poumon
JP7165329B2 (ja) * 2017-04-28 2022-11-04 東レ株式会社 卵巣腫瘍の検出のためのキット、デバイス及び方法
US20220359037A1 (en) * 2018-03-23 2022-11-10 The Regents Of The University Of California Non-Invasive Classification of Benign and Malignant Melanocytic Lesions Using MicroRNA Profiling
JP2020188683A (ja) * 2019-05-17 2020-11-26 株式会社Ａｌｄｏｃｋ 胃癌または食道癌を検出するための癌マーカー

Also Published As

Publication number Publication date
JP2024523848A (ja) 2024-07-02
WO2022261039A3 (fr) 2023-01-19
EP4352266A4 (fr) 2025-12-10
EP4352266A2 (fr) 2024-04-17
WO2022261039A2 (fr) 2022-12-15
AU2022289858A1 (en) 2024-01-04
CN117500941A (zh) 2024-02-02

Similar Documents

Publication Publication Date Title
CA3221494A1 (fr) Methode, kit et systeme de detection de cancer
JP5415963B2 (ja) 新しい癌マーカー
US11198909B2 (en) Risk scores based on human phosphodiesterase 4D variant 7 expression
JP2014509189A (ja) 結腸ガン遺伝子発現シグネチャーおよび使用方法
JP2009508493A (ja) すい臓がんを診断するための方法
EP3548631B1 (fr) Évaluation de risque sur la base d'expression de 7 variante 4d de phosphodiestérase humaine
AU2026202126A1 (en) Biomarkers for renal cell carcinoma
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
JP6611411B2 (ja) 膵臓がんの検出キット及び検出方法
US20170283877A1 (en) Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
JP2024519082A (ja) 肝細胞がんのｄｎａメチル化バイオマーカー
JP6383541B2 (ja) 胆管がんの検出キット及び検出方法
CN111315897B (zh) 用于黑素瘤检测的方法
US20240209451A1 (en) Cancer detection method, kit, and system
CN110387423A (zh) 前庭神经鞘瘤诊断用生物标志物
Bender et al. LASSO logistic regression reveals a mixed MiRNA and serum-marker classifier for prediction of immunotherapy response in liquid biopsies of melanoma patients
CN114746551A (zh) 大肠癌诊断用标志物、辅助大肠癌的诊断的方法、收集数据以用于大肠癌诊断的方法、大肠癌的诊断试剂盒、大肠癌治疗药物、大肠癌的治疗方法、大肠癌的诊断方法
KR20250159710A (ko) 암 진단 모델의 개발 방법 및 암 검출 방법 개발에서의 이의 용도
US20260035748A1 (en) Methods for detecting and treating idiopathic pulmonary fibrosis
HK40126608A (zh) 开发癌症诊断模型的方法及其在开发癌症检测方法中的用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250602

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250602

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20260201

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20260201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260201